Cargando…

Extent and prognostic value of MGMT promotor methylation in glioma WHO grade II

MGMT promotor methylation is associated with favourable outcome in high-grade glioma. In glioma WHO grade II, it is unclear whether the extent of MGMT promotor methylation and its prognostic role is independent from other molecular markers. We performed a retrospective analysis of 155 patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karschnia, Philipp, Teske, Nico, Dorostkar, Mario M., Siller, Sebastian, Weller, Jonathan, Baehring, Joachim M., Dietrich, Jorg, von Baumgarten, Louisa, Herms, Jochen, Tonn, Joerg-Christian, Thon, Niklas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661705/ https://www.ncbi.nlm.nih.gov/pubmed/33184319 http://dx.doi.org/10.1038/s41598-020-76312-x

Ejemplares similares

Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?
por: Teske, Nico, et al.
Publicado: (2021)

Subventricular zone involvement is associated with worse outcome in glioma WHO grade 2 depending on molecular markers
por: Karschnia, Philipp, et al.
Publicado: (2021)

Shunt dependency in supratentorial intraventricular tumors depends on the extent of tumor resection
por: Teske, Nico, et al.
Publicado: (2023)

Advanced imaging findings in stroke-like migraine attacks after radiation therapy (SMART) syndrome
por: Teske, Nico, et al.
Publicado: (2022)

CAR T-Cells for CNS Lymphoma: Driving into New Terrain?
por: Karschnia, Philipp, et al.
Publicado: (2021)

Treatment benefit in patients aged 80 years or older with biopsy-proven and non-resected glioblastoma is dependent on MGMT promoter methylation status
por: Weller, Jonathan, et al.
Publicado: (2023)

Frequency and Prognostic Relevance of Volumetric MRI Changes in Contrast- and Non-Contrast-Enhancing Tumor Compartments between Surgery and Radiotherapy of IDHwt Glioblastoma
por: Teske, Nico, et al.
Publicado: (2023)

Significance of molecular diagnostics for therapeutic decision-making in recurrent glioma
por: Blobner, Jens, et al.
Publicado: (2023)

O(6)-Methylguanine-DNA Methyltransferase (MGMT) mRNA Expression Predicts Outcome in Malignant Glioma Independent of MGMT Promoter Methylation
por: Kreth, Simone, et al.
Publicado: (2011)

The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents
por: Siller, Sebastian, et al.
Publicado: (2021)

In vivo two-photon characterization of tumor-associated macrophages and microglia (TAM/M) and CX3CR1 during different steps of brain metastasis formation from lung cancer
por: Zhang, Wenlong, et al.
Publicado: (2021)

Diagnostic Yield and Complication Rate of Stereotactic Biopsies in Precision Medicine of Gliomas
por: Katzendobler, Sophie, et al.
Publicado: (2022)

PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression
por: Weller, Jonathan, et al.
Publicado: (2021)

The surgical perspective in precision treatment of diffuse gliomas
por: Thon, Niklas, et al.
Publicado: (2019)

The value of stereotactic biopsy of primary and recurrent brain metastases in the era of precision medicine
por: Katzendobler, Sophie, et al.
Publicado: (2022)

Appraisal of re-irradiation for the recurrent glioblastoma in the era of MGMT promotor methylation
por: Kim, Il Han
Publicado: (2019)

Increased TSPO PET signal after radiochemotherapy in IDH-wildtype glioma—indicator for treatment-induced immune activation?
por: Quach, Stefanie, et al.
Publicado: (2022)

Interstitial Photodynamic Therapy Using 5-ALA for Malignant Glioma Recurrences
por: Lietke, Stefanie, et al.
Publicado: (2021)

TSPO PET signal using [(18)F]GE180 is associated with survival in recurrent gliomas
por: Quach, Stefanie, et al.
Publicado: (2022)

Mutational signature of extracranial meningioma metastases and their respective primary tumors
por: Biczok, A., et al.
Publicado: (2023)

Personalized treatment strategies in glioblastoma: MGMT promoter methylation status
por: Thon, Niklas, et al.
Publicado: (2013)

TERT promotor status does not add prognostic information in IDH-wildtype glioblastomas fulfilling other diagnostic WHO criteria: A report of the RANO resect group
por: Karschnia, Philipp, et al.
Publicado: (2022)

Clinicopathologic Findings in Fatal Neurotoxicity After Adoptive Immunotherapy With CD19-Directed CAR T-Cells
por: Karschnia, Philipp, et al.
Publicado: (2021)

SURG-10. The evolving role of neurosurgery for central nervous system metastases in the era of personalized medicine
por: Karschnia, Philipp, et al.
Publicado: (2021)

In vivo dynamics and anti-tumor effects of EpCAM-directed CAR T-cells against brain metastases from lung cancer
por: Xu, Tao, et al.
Publicado: (2023)

L-type amino acid transporter (LAT) 1 expression in (18)F-FET-negative gliomas
por: Vettermann, Franziska J., et al.
Publicado: (2021)

Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide
por: Brawanski, Konstantin R., et al.
Publicado: (2023)

Prognostic Value of TSPO PET Before Radiotherapy in Newly Diagnosed IDH–Wild-Type Glioblastoma
por: Albert, Nathalie L., et al.
Publicado: (2023)

Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group
por: Karschnia, Philipp, et al.
Publicado: (2022)

Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy
por: Dunn, J, et al.
Publicado: (2009)

Do we really know who has an MGMT methylated glioma? Results of an international survey regarding use of MGMT analyses for glioma
por: Malmström, Annika, et al.
Publicado: (2020)

Improved risk stratification in younger IDH wild-type glioblastoma patients by combining a 4-miRNA signature with MGMT promoter methylation status
por: Unger, Kristian, et al.
Publicado: (2020)

Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group
por: Karschnia, Philipp, et al.
Publicado: (2023)

Alu hypomethylation and MGMT hypermethylation in serum as biomarkers of glioma
por: Gong, Mingjie, et al.
Publicado: (2017)

MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas
por: Oldrini, Barbara, et al.
Publicado: (2020)

The Significance of MGMT Promoter Methylation Status in Diffuse Glioma
por: Jovanović, Nikola, et al.
Publicado: (2022)

Age-Dependent Impact of Concomitant Radio-Chemotherapy and MGMT Promotor Methylation on PFS and OS in Patients with IDH Wild-Type Glioblastoma: The Real-Life Data
por: Krigers, Aleksandrs, et al.
Publicado: (2022)

Radiation necrosis after a combination of external beam radiotherapy and iodine-125 brachytherapy in gliomas
por: Hadi, Indrawati, et al.
Publicado: (2021)

Molecular diagnostics helps to identify distinct subgroups of spinal astrocytomas
por: Biczok, Annamaria, et al.
Publicado: (2021)

Multifocal high-grade glioma radiotherapy safety and efficacy
por: Fleischmann, Daniel Felix, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m96bao44mihfq05llh7q76i35r